Literature DB >> 25880592

Potential effects of age on screening for primary aldosteronism.

Q Luo1, N F Li1, X G Yao1, D L Zhang1, S F Y Abulikemu1, G J Chang1, K M Zhou1, G L Wang1, M H Wang1, W J Ouyang1, Q Y Cheng1, Y Jia1.   

Abstract

Aldosterone/renin ratio (ARR) is currently regarded as the most reliable and available screening test for primary aldosteronism (PA), however, the falling accuracy of ARR with increasing age has posed crucial challenge for PA screening among older-aged population. To clarify potential effects of age on screening for PA, 216 subjects with PA and 657 subjects with non-PA were recruited and subdivided into four age groups (⩽39, 40-49, 50-59 and ⩾60 years) and their biochemical parameters were compared. As expected, plasma renin activity (PRA) lowered more than plasma aldosterone concentration (PAC) and led to gradually elevated ARR with increasing age in the non-PA group (P<0.001), whereas this phenomenon was unconspicuous in the PA group. The best cut-off values of ARR for PA screening were elevated in subjects ⩾50 years, whereas the area under the receiver operating characteristic curves (AUCs), sensitivity, specificity and Youden's index (YI) of ARR were declined with increasing age, especially in patients ⩾60 years (AUC=0.863, sensitivity=95.2%, specificity=69.0%, YI=0.643). The AUCs of PAC increased with increasing age and even slightly surpassed that of ARR in patients ⩾60 years (AUCPAC=0.884). Our data suggest that the criteria of ARR for PA screening in patients ⩾50 years may need setting higher; the falling accuracy of ARR with increasing age, especially in patients ⩾60 years, could be improved by taking into account the absolute value of the PAC when applicable by the center.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25880592     DOI: 10.1038/jhh.2015.21

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  35 in total

1.  Inappropriate left ventricular mass in patients with primary aldosteronism.

Authors:  Maria Lorenza Muiesan; Massimo Salvetti; Anna Paini; Claudia Agabiti-Rosei; Cristina Monteduro; Gloria Galbassini; Eugenia Belotti; Carlo Aggiusti; Damiano Rizzoni; Maurizio Castellano; Enrico Agabiti-Rosei
Journal:  Hypertension       Date:  2008-07-21       Impact factor: 10.190

2.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase? Results of a preliminary study.

Authors:  Ashraf H Ahmed; Richard D Gordon; Gregory Ward; Martin Wolley; Cynthia Kogovsek; Michael Stowasser
Journal:  Clin Endocrinol (Oxf)       Date:  2015-02-03       Impact factor: 3.478

5.  Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting.

Authors:  Teresa Gijón-Conde; Auxiliadora Graciani; José R Banegas
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2014-02-05

6.  High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.

Authors:  Michael Stowasser; Richard D Gordon; Thanuja G Gunasekera; Diane C Cowley; Gregory Ward; Colin Archibald; B Mark Smithers
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

7.  Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry.

Authors:  Paul J Taylor; Donald P Cooper; Richard D Gordon; Michael Stowasser
Journal:  Clin Chem       Date:  2009-04-09       Impact factor: 8.327

8.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.

Authors:  E Florczak; A Prejbisz; E Szwench-Pietrasz; P Sliwiński; P Bieleń; A Klisiewicz; I Michałowska; E Warchoł; M Januszewicz; M Kała; A Witkowski; A Więcek; K Narkiewicz; V K Somers; A Januszewicz
Journal:  J Hum Hypertens       Date:  2013-05-23       Impact factor: 3.012

10.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

View more
  11 in total

1.  Plasma aldosterone concentration is associated with white matter lesions in patients with primary aldosteronism.

Authors:  Yujuan Yuan; Nanfang Li; Yan Liu; Menghui Wang; Mulalibieke Heizhati; Qing Zhu; Xiaoguang Yao; Qin Luo
Journal:  Endocrine       Date:  2021-11-15       Impact factor: 3.633

2.  Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-18       Impact factor: 3.738

3.  Association Between Polymorphisms of ADRBK1 Gene and Plasma Renin Activity in Hypertensive Patients: A Case-Control Study.

Authors:  Yu Li; Nanfang Li; Xiaoguang Yao; Mulalibieke Heizati; Delian Zhang; Qing Zhu; Guijuan Chang; Xiangyang Zhang
Journal:  Med Sci Monit       Date:  2016-08-24

4.  Age-Related Cutoffs of Plasma Aldosterone/Renin Concentration for Primary Aldosteronism Screening.

Authors:  Linqiang Ma; Ying Song; Mei Mei; Wenwen He; Jinbo Hu; Qingfeng Cheng; Ziwei Tang; Ting Luo; Yue Wang; Qianna Zhen; Zhihong Wang; Hua Qing; Yihong He; Qifu Li; Shumin Yang
Journal:  Int J Endocrinol       Date:  2018-07-16       Impact factor: 3.257

5.  Minor Change of Plasma Renin Activity during the Saline Infusion Test Provide an Auxiliary Diagnostic Value for Primary Aldosteronism.

Authors:  Munire Adilijiang; Qin Luo; Menghui Wang; Delian Zhang; Xiaoguang Yao; Guoliang Wang; Keming Zhou; Nanfang Li
Journal:  Int J Endocrinol       Date:  2021-02-17       Impact factor: 3.257

6.  Positive Association Between Plasma Aldosterone Concentration and White Matter Lesions in Patients With Hypertension.

Authors:  Yujuan Yuan; Nanfang Li; Yan Liu; Qing Zhu; Mulalibieke Heizhati; Weiwei Zhang; Xiaoguang Yao; Deilian Zhang; Qin Luo; Menghui Wang; Guijuan Chang; Mei Cao; Keming Zhou; Lei Wang; Junli Hu; Nuerguli Maimaiti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

7.  Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study.

Authors:  Mengyue Lin; Mulalibieke Heizhati; Lin Gan; Xiaoguang Yao; Qin Luo; Delian Zhang; Suofeiya Abulikemu; Menghui Wang; Guoliang Wang; Wen Jiang; Junli Hu; Nuerguli Maimaiti; Lei Wang; Ting Wu; Le Sun; Na Yue; Yingli Ren; Nanfang Li
Journal:  J Hypertens       Date:  2022-03-01       Impact factor: 4.844

8.  Higher plasma renin activity is associated with increased kidney damage risk in patients with hypertension and glucose metabolic disorders.

Authors:  Mengyue Lin; Mulalibieke Heizhati; Lin Gan; Jing Hong; Ting Wu; Zuhere Xiamili; Ling Tong; Yue Lin; Nanfang Li
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-05-06       Impact factor: 2.885

9.  The Association between eGFR and the Aldosterone-to-Renin Ratio and Its Effect on Screening for Primary Aldosteronism.

Authors:  Jing Xu; Yumei Yang; Yan Ling; Zhiqiang Lu; Xin Gao; Xiaomu Li; Xiaoying Li
Journal:  Int J Endocrinol       Date:  2020-02-07       Impact factor: 3.257

Review 10.  Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature.

Authors:  Gregory P Veldhuizen; Rawan M Alnazer; Abraham A Kroon; Peter W de Leeuw
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-12-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.